OPR - Delayed Quote • USD BIOR Jul 2024 4.000 call (BIOR240719C00004000) Follow 0.1000 0.0000 (0.00%) At close: March 8 at 9:47 AM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for BIOR240719C00004000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: BIOR Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Biora Therapeutics Full Year 2023 Earnings: Beats Expectations Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules BIOR: Negotiations Accelerating Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript Q4 2023 Biora Therapeutics Inc Earnings Call Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
